AstraZeneca PLC (AZN)vsSight Sciences Inc (SGHT)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
SGHT
Sight Sciences Inc
$4.09
+3.02%
HEALTHCARE · Cap: $237.20M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 75826% more annual revenue ($58.74B vs $77.36M). AZN leads profitability with a 17.4% profit margin vs -49.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SGHT
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+36.9%
Fair Value
$8.76
Current Price
$4.09
$4.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -50.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : SGHT
SGHT has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : SGHT
The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.49 — expect wider price swings.
SGHT is growing revenue faster at 6.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.4% margins. SGHT offers better value entry with a 36.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is a leading medical technology innovator dedicated to revolutionizing the management of eye diseases, particularly glaucoma, through both surgical and non-surgical solutions. The company boasts a diverse array of advanced products and a solid intellectual property portfolio, strategically positioning it to leverage the growing demand for minimally invasive ophthalmic therapies. As Sight Sciences continues to enhance its distribution capabilities and push the boundaries of eye care technology, it represents a compelling investment opportunity for institutional investors seeking exposure in the evolving healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?